Results · Apr-Jun 2026
Mangalam Drugs and Organics Q1 FY27 results
Sales was flat at ₹57.1 crore against Apr-Jun 2025.
Operating profit was ₹0.9 crore, an operating margin of 1.6% (up 9.4 points from a year ago).
The net loss narrowed to ₹7.6 crore from ₹13.8 crore.
Against Jan-Mar 2026: sales −15%, loss narrows.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 57.1 | 57.3 | −0% |
| Operating profit (EBITDA) | 0.9 | -4.5 | n/m |
| Operating margin | 1.6% | −7.8% | +9.4 pts |
| Net profit | -7.6 | -13.8 | loss narrows |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.